Abstract

BackgroundAdvance research directives (ARD) have been suggested as a means by which to facilitate research with incapacitated subjects, in particular in the context of dementia research. However, established disclosure requirements for study participation raise an ethical problem for the application of ARDs: While regular consent procedures call for detailed information on a specific study (“token disclosure”), ARDs can typically only include generic information (“type disclosure”). The introduction of ARDs could thus establish a double standard in the sense that within the context of ARDs, type disclosure would be considered sufficient, while beyond this context, token disclosure would remain necessary.Main bodyThis paper provides an ethical analysis of ARDs, taking into account the results of numerous empirical studies that have been performed so far. It will be argued that a revised understanding of informed consent can allow for context-sensitive disclosure standards. As a consequence, ARDs that include type disclosure can be acceptable under suitable circumstances. Such an approach raises a number of objections. A thorough examination shows, however, that they are not sufficient to justify a rejection of the approach.ConclusionThe approach presented in this paper avoids introducing a double standard. It is, therefore, more suitable for the implementation of ARDs than established approaches.

Highlights

  • ConclusionThe approach presented in this paper avoids introducing a double standard. It is, more suitable for the implementation of Advance research directives (ARD) than established approaches

  • Advance research directives (ARD) have been suggested as a means by which to facilitate research with incapacitated subjects, in particular in the context of dementia research

  • The approach presented in this paper avoids introducing a double standard

Read more

Summary

Conclusion

Advance research directives have been suggested as a suitable amendment to the principle of informed consent in order to allow for research with participants with neurodegenerative diseases, in particular dementia. According to the established model of informed consent, the quality of consent is directly correlated with the degree of the patient’s understanding and, token disclosure is deemed to be essential Against this background, type disclosure appears to be secondrate and its introduction for a vulnerable population is ethically highly problematic. According to an alternative understanding, informed consent should be seen as a communicative act Such a view renders it possible to apply a more context-sensitive disclosure standard. Type disclosure can be acceptable under suitable circumstances for various kinds of research projects Such an approach avoids introducing a double standard for particular types of research such as dementia research and is, more convincing from an ethical point of view.

Background
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call